Outlook Therapeutics, Inc. has announced the participation of Dr. Jennifer Kissner, Senior Vice President of Clinical Development, in a Virtual Investor segment discussing the 12-week safety and ...
You Software hopes there's big money in making little improvements to Microsoft products. The start-up company made its retail debut Wednesday with You Perform, a collection of more than a dozen ...
Outlook Therapeutics (OTLK) has made significant progress in advancing the use of its drug ONS-5010, which is being developed for the treatment of patients with wet age-related macular degeneration ...
ISELIN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ ...
NORSE EIGHT study on track to commence in Q1 2024 Resubmission of ONS-5010 Biologics License Application (BLA) in the U.S. expected by the end of calendar year 2024 ISELIN, N.J., Dec. 19, 2023 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results